Fig. 4
From: Discovery of a Proteolysis Targeting Chimera for TRKA and RET-derived oncoproteins
Compound 9 activity on RET- and TRKA-driven cell proliferation. The indicated cell lines were incubated with vehicle (NT: not treated) or increasing concentrations of compound 9 and counted at the indicated time points. Data are the mean ± SD of a single experiment performed in triplicate. Number of cells plated at Day 0: KM12 (10,000/well); TT (200,000/well); TPC-1 (5000/well); MZ-CRC-1 and Lc-2/ad (100,000/well). IC50 dose was calculated using PRIZM software (GraphPad Software Inc). Confidence intervals are indicated in brackets.
